跳至主要内容

Medicilon was selected into the first batch of Shanghai innovative enterprise headquarters

 On December 5, the awarding ceremony for the first batch of Shanghai innovative enterprise headquarters was held.  Zheng Gong, Deputy Secretary of the Shanghai Municipal Party Committee and Mayor, awarded plaques to 40 innovative enterprise headquarters and took a group photo.  Shanghai Medicilon Inc. (Medicilon) has become one of the first 10 biopharmaceutical companies selected as Shanghai's innovative enterprise headquarters.  This is the first time that Shanghai has independently recognized the headquarters of innovative enterprises, providing support to accelerate the development of Shanghai's innovative economy and build a technological innovation center with global influence.  This honor signifies that Medicilon's performance in technological innovation in new drug research and development has been highly recognized by the Shanghai Municipal Government.

 Medicilon was selected into the first batch of Shanghai innovative enterprise headquarters.webp

The 40 innovative enterprise headquarters awarded licenses this time cover key industrial fields such as integrated circuits, biopharmaceutical, artificial intelligence, and digital economy.  It mainly presents the following characteristics:

One is strong leadership.  The licensed companies are mainly leading companies and technological innovation leaders in their respective industries. More than 90% of the company's products and services rank among the top in domestic and global market shares, and have strong industry position.

Second is strong innovation ability.  Licensed companies invest heavily in R&D. More than 50% of them have Class I new drugs or “first-of-its-kind” products domestically or globally, and more than 10% of them have won national or local science and technology progress awards.

Third is high growth potential.  The licensing companies are all market entities with good development momentum in recent years.  In recent years, 22 companies have been listed globally, showing strong development vitality. More than 60% of the companies have achieved a compound growth rate of more than 30% in operating income in the past three years, achieving rapid growth.

Fourth is the distinct agglomeration development . The regional agglomeration effect of licensed enterprises is relatively consistent with the development positioning of strategic emerging industry clusters in each district.

In addition, all licensing companies have more than two branches or subsidiaries outside Shanghai. The Shanghai headquarters has complex and multiple functions such as management, settlement, and R&D.  Most companies have also achieved global layout.

As one of the first batch of innovative enterprise headquarters selected in Shanghai, Medicilon has focused on the field of pre-clinical research and development of biomedicine since its establishment in 2004, focusing on the needs of new drug research and development.  With its innovative R&D technology and hard-core R&D strength, Medicilon continues to empower the development of the biopharmaceutical industry by focusing on cutting-edge fields such as nucleic acid drugs, cellular immunity, mRNA, PROTAC, ADC, and bi/multispecific antibodies, which integrates a one-stop biopharmaceutical preclinical R&D service platform.

According to the "Shanghai Innovative Enterprise Headquarters Recognition and Reward Management Measurement" issued on February 22, 2023, Medicilon will subsequently enjoy a number of preferential policies such as financial support, talent introduction, and tax incentives provided by the Shanghai Municipal Government.  These will further help Medicilon to show more achievements in empowering the research and development of new drugs.

Being recognized as one of the first batch of innovative enterprise headquarters in Shanghai is not only an affirmation of Medicilon's efforts in empowering innovative drug research and development in the past nearly two decades, but also trust in the company's future development.  This honor will encourage Medicilon to continue to establish a hard technology moat and make greater contributions to promoting the innovation and development of biopharmaceutical in Shanghai and China.

About Innovative Enterprise Headquarters
In order to accelerate the development of Shanghai's innovative economy, the Shanghai Municipal Government encourages various innovative entities such as high-tech enterprises, specialized new enterprises, and corporate technology centers to further improve their capabilities, accelerate the creation of composite enterprise headquarters, and provide support for the construction of a technological innovation center with global influence.  The innovative enterprise headquarters focuses on key areas of strategic emerging industries, independently owns the core intellectual property rights of domestically and internationally influential products or services locally, and leads the industry in overall technical level and innovation capabilities, have important advantages and high growth in market competition, make an important contribution to local economic and social development or play a leading role, and have control or exercise management rights over their cross-regional branches or businesses).

评论

此博客中的热门博文

What is preclinical testing?

In the process of  preclinical testing  of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a  preclinical research  phase followed, before which, as described above, the potential toxicity of the compou

Inventory of the three major in vitro pharmacokinetic research methods

  The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in  Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati